Discovery of a novel ROS-based signature for predicting prognosis and immunosuppressive tumor microenvironment in lung adenocarcinoma

Yufeng Guo ^1,2, Geyun Chang ³, Rui Wan ^1,2

⁰National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 100021.

Journal of Cancer +

|

April 5, 2024

View abstract on PubMed

Summary

Reactive oxygen species (ROS) significantly impact lung adenocarcinoma (LUAD) progression. A novel ROS-related gene signature predicts LUAD patient outcomes and immunotherapy response, offering new therapeutic strategies.

Area Of Science

Oncology
Molecular Biology
Immunology

Background

Reactive oxygen species (ROS) play a crucial role in lung adenocarcinoma (LUAD) development and progression.
The precise pathways and clinical significance of ROS-related genes in LUAD are not fully understood.
Targeting ROS presents a potential therapeutic avenue for LUAD.

Purpose Of The Study

To identify a ROS-related gene signature in LUAD.
To evaluate the predictive value of this signature for LUAD patient outcomes and immunotherapy response.
To explore the relationship between the ROS signature and antitumor immunity.

Main Methods

Comprehensive analysis of 1494 LUAD cases from The Cancer Genome Atlas, Gene Expression Omnibus, and a Chinese LUAD cohort.
Identification and validation of a ROS-related gene signature.
Assessment of the signature's correlation with clinical outcomes, antitumor immunity, and immunotherapy response.

Main Results

A ROS-related gene signature with substantial predictive value in LUAD patient cohorts was identified.
The signature showed a significant negative correlation with antitumor immunity, including dendritic cell maturation and activation.
The ROS-related signature demonstrated predictive value for immunotherapy outcomes in LUAD and other solid tumors.

Conclusions

The identified ROS-related signature serves as a valuable predictive tool for LUAD.
This signature offers new insights into the interplay between ROS, antitumor immunity, and immunotherapy efficacy in LUAD.
Findings support refining clinical assessments and tailoring immunotherapeutic strategies for LUAD patients.

Keywords:

LUAD ROS dendritic cells immunotherapy tumor microenvironment.